Antiaversive effects of 5HT(2C) receptor agonists and fluoxetine in a model of panic-like anxiety in rats

European Neuropsychopharmacology

Volumn 8, Issue 3, 1998, Pages 161-168

  Jenck, François ^a   Moreau, Jean Luc ^a   Berendsen, Hemmie H g ^b   Boes, Michael ^a   Broekkamp, Chris L e ^b   Martin, James R ^a   Wichmann, Jürgen ^a   Van Delft, Anton M l ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b Neuropharmacology Department   (Netherlands)

Author keywords

5HT(2C); Animal model; Anxiety; Brain stimulation; Panic; Serotonin; SSRI

Indexed keywords

2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; ALPRAZOLAM; ANTIPANIC AGENT; CLONAZEPAM; FLUOXETINE; ORG 12962; RECEPTOR SUBTYPE; RO 600332; SEROTONIN AGONIST; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG; ETHYLAMINE; INDOLE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ELECTROSTIMULATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PANIC; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; RAT; ANIMAL; BRAIN; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; ESCAPE BEHAVIOR; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

ANIMALS; ANXIETY; BRAIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCAPE REACTION; ETHYLAMINES; FLUOXETINE; INDOLES; INJECTIONS, INTRAPERITONEAL; MALE; PANIC; PERIAQUEDUCTAL GRAY; RATS; RATS, WISTAR; SEROTONIN AGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0032129170     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(97)00055-2     Document Type: Article

References (65)

1. Abramowski D., Rigo M., Duc D., Hoyer D., Staufenbiel M. Localization of the 5-hydroxytryptamine 2C receptor protein in human and rat brain using specific antisera. Neuropharmacology. 34:1995;1635-1645.
2. 2C receptors. Biol. Psychiatry. 39:1996;1000-1008.
3. Allikmets L., Matto V., Harro J. Do the antidepressants have anxiogenic action? Biol. Psychiatry. 39:1996;626.
4. Altemus M., Paletzki R., Gerfen C.R., Murphy D.L. Differential activation of ZIF268 in the amygdala in response to mCPP. Biol. Psychiatry. 39:1996;583.
5. Barker E.L., Sanders-Bush E. 5-Hydroxytryptamine 1C receptor density and mRNA levels in choroid plexus epithelial cells after treatment with mianserin and (-)-1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane. Mol. Pharmacol. 44:1993;725-730.
6. 1 receptor agonists administered into the periaqueductal gray. Psychopharmacology. 108:1992;110-114.
7. Benjamin J., Greenberg B.D., Murphy D.L. Daily administration of m-chlorophenylpiperazine to healthy human volunteers rapidly attenuates many of its behavioral, hormonal, cardiovascular and temperature effects. Psychopharmacology. 127:1996;140-149.
8. Berendsen H.H.G., Broekkamp C.L.E. Drug-induced penile erections in rats: indications of serotonin 1B receptor mediation Eur. J. Pharmacol. 135:1987;279-287.
9. Berendsen H.H.G., Broekkamp C.L.E. Comparison of stimulus properties of fluoxetine and 5HT receptor agonists in a conditioned taste aversion procedure. Eur. J. Pharmacol. 253:1994;83-89.
10. Broekkamp C.L.E., Berendsen H.H.G., Jenck F., Van Delft A.M.L. Animal models for anxiety and response to serotonergic drugs. Psychopathology. 22(suppl 1):1989;2-12.
11. Broekkamp C.L.E. Does it matter which serotonin receptor is doing what? J. Psychopharmacology. 5:1991;320-321.
12. 1C sites. Eur. J. Pharmacol. 191:1990;93-96.
13. Charney D.S., Woods S.W., Goodman W.K., Heninger G.R. Serotonin function in anxiety. II. Effects of the serotonin agonist mCPP in panic disorder patients and healthy subjects. Psychopharmacology. 92:1987;14-24.
14. Deakin J.W.F., Graeff F.G. 5HT and mechanisms of defence. J. Psychopharmacology. 5:1991;305-315.
15. Delgado J.M., Robert W., Miller N.E. Learning motivated by electrical stimulation of the brain stem. Am. J. Physiol. 179:1954;587-593.
16. Den Boer J.A., Westenberg H.G.M. Effects of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int. Clin. Psychopharmacol. 3:1988;59-74.
17. Dolberg O.T., Sasson Y., Cohen R., Zohar J. The relevance of behavioral probes in obsessive-compulsive disorder. Eur. J. Neuropsychopharmacol. 5(3):1995;161-162.
18. 2C receptor-mediated phosphoinositide turnover and the stimulus effects of m-chlorophenylpiperazine. Psychopharmacology. 122:1995;237-243.
19. 2C receptor responsiveness occurs on rearing rats in social isolation. Psychopharmacology. 123:1996;346-352.
20. 1C receptor antagonist. J. Med. Chem. 36:1993;1104-1107.
21. Goodwin G.M. How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. J. Clin. Psychiatry. 57(suppl 4):1996;9-13.
22. Graeff F.G., Guimaraes F.S., De Andrade T.G.C.S., Deakin J.W.F. Role of 5HT in stress, anxiety and depression. Pharmacol. Biochem. Behav. 54:1996;129-141.
23. Griebel G., Moreau J.L., Jenck F., Misslin R., Martin J.R. Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents. Psychopharmacology. 113:1994;463-470.
24. Hamik A., Peroutka S.J. 1-(m-Chlorophenyl)-piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol. Psychiatry. 25:1989;569-575.
25. 1B agonist, produces prolactin, cortisol and growth hormone release and biphasic behavioral changes in healthy human subjects. Soc. Neurosci. Abstr. 11:1985;1256.
26. Hetem L.A.B., De Souza C.J., Guimaraes F.S., Zuardi A.W., Graeff F.G. Effect of D-fenfluramine on human experimental anxiety. Psychopharmacology. 127:1996;276-282.
27. Huidobro-Toro J.P., Harris R.A. Brain lipids that induce sleep are novel modulators of 5-hydroxytryptamine receptors. Proc. Natl. Acad. Sci. USA. 93:1996;8078-8082.
28. 1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur. J. Pharmacol. 231:1993;223-229.
29. 1C) receptors on periaqueductal gray aversion. Eur. J. Pharmacol. 161:1989;219-221.
30. Jenck F., Moreau J.L., Martin J.R. Dorsal periaqueductal gray-induced aversion as a simulation of panic anxiety: elements of face and predictive validity. Psychiatry Res. 57:1995;181-191.
31. Jenck F., Broekkamp C.L.E., Van Delft A.M.L. The effects of antidepressants on aversive periaqueductal stimulation in rats. Eur. J. Pharmacol. 177:1990;201-204.
32. Kahn R.S., Asnis G.M., Wetzler S., Van Praag H.M. Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology. 96:1988;360-364.
33. 2B receptor antagonist. Br. J. Pharmacol. 111:1994;797-802.
34. 2B receptor antagonist in two conflict models of anxiety. Psychopharmacology. 118:1995;178-182.
35. Klein E., Zohar J., Geraci M.F., Murphy D.L., Uhde T.W. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects. Biol. Psychiatry. 30:1991;973-984.
36. 1C receptor antagonists. Eur. J. Pharmacol. Mol. Pharmacol. Sect. 245:1993;179-182.
37. Lecrubier Y. SSRIs in panic disorder. Eur. Neuropsychopharmacology. 5:1995;184.
38. Leonard H.L., Topol D., Bukstein O., Hindmarsh D., Allen A.J., Swedo S.E. Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder. J. Am. Acad. Child Adolesc. Psychiatry. 33(6):1994;792-794.
39. Lima L. Region-selective reduction of brain serotonin turnover rate and serotonin agonist-induced behavior in mice treated with clonazepam. Pharmacol. Biochem. Behav. 39:1991;671-676.
40. Loi V., Lai M., Pisano M.R., Del Zompo M. Panicogenic effect of sumatriptan: a pilot study. Pharmacol. Res. 31(Suppl):1995;348.
41. Marek G.J., McDougle C.J., Price L.H., Seiden L.S. A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Pschopharmacology. 109:1992;1-11.
42. 2C receptor agonists and antagonists in animal models of anxiety. Eur. Neuropsychopharmacol. 5:1995;209.
43. Mellow A.M., Lawlor B.A., Sunderland T., Mueller E.A., Molchan S.E., Murphy D.L. Effects of daily oral m-chlorophenylpiperazine in elderly depressed patients: initial experience with a serotonin agonist. Biol. Psychiatry. 28:1990;588-594.
44. Mengod G., Nguyen H., Le H., Waeber C., Lübbert H., Palacios J.M. The distribution and cellular localization of the serotonin 1C receptor mRNA in the rodent brain examined by in situ hybridization histochemistry. Comparison with receptor binding distribution. Neuroscience. 15:1990;577-591.
45. 1C receptor is a prominent serotonin receptor subtype in the central nervous system. Proc. Natl. Acad. Sci. USA. 86:1989;6793-6797.
46. 1C receptor activation in rats. Psychopharmacology. 110:1993;140-144.
47. 2C receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats. Eur. Neuropsychopharmacol. 6:1996;169-175.
48. Nashold B.S., Wilson W.P., Slaughter D.G. Sensations evoked by stimulation of the midbrain of man. J. Neurosurg. 30:1969;14-24.
49. Nutt D., Lawson C. Panic attacks. A neurochemical overview of models and mechanisms. Br. J. Psychiatry. 160:1992;165-178.
50. 2C receptor. Psychopharmacology. 126:1996;234-240.
51. Paxinos, G., Watson, C., 1982. The rat brain in stereotaxic coordinates. Academic Press, New York.
52. Pigott, T.A., L'Heureux, F., Bernstein,S.E., Hill, J.L., Murphy, D.L., 1992. A controlled comparative therapeutic trial of clomipramine and m-chlorophenylpiperazine (mCPP) in patients with obsessive-compulsive disorder. NCDEU Annual Meeting Abstract, May, pp. 26-29.
53. 2C receptors. Mol. Brain Res. 23:1994;163-178.
54. 1C/2 receptor agonists and antagonists. Eur. J. Pharmacol. Mol. Pharmacol. Sect. 244:1993;1-5.
55. Prisco S., Esposito E. Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. Br. J. Pharmacol. 116:1995;1923-1931.
56. 3 Antagonists and Benzodiazepines: their Comparative Behavioral Pharmacology, John Wiley and Sons, pp. 1-30.
57. Schmitt P., Sandner G., Karli P. Escape and approach induced by brain stimulation: a parametric analysis. Behav. Brain Res. 2:1981;49-79.
58. Schmitt, P., Di Scala, G., Jenck, F., Sandner, G., 1984. Periventricular structures, elaboration of aversive effects and processing of sensory information. In: Modulation of Sensorimotor Activity during Alterations in Behavioral States. Alan R. Liss, New York, pp. 393-414.
59. Smith, W.T, Londborg, P.D., Glaudin, V., Painter, J.R., 1996. Clonazepam augmentation of fluoxetine in the treatment of outpatients with major depression: a double-blind, placebo-controlled, multicenter study. Psychopharmacol. Bull., in press.
60. Swiss Academy of Medical Sciences and Swiss Academy of Science Ethical principles and guidelines for experiments on animals. Experientia. 51:1995;1-3.
61. 2C serotonin receptors. Nature. 374:1995;542-546.
62. 2B receptor. Neuroreport. 7:1996;1457-1460.
63. 1A receptor agonist flesinoxan in panic disorder. Psychopharmacology. 127:1996;174-180.
64. Westenberg H.G.M., Den Boer J.A. New findings in the treatment of panic disorder. Pharmacopsychiatry. 26:1993;30-33.
65. Westphal R.S., Sanders-Bush E. Reciprocal binding properties of 5-hydroxytryptamine type 2C receptor agonists and inverse agonists. J. Pharmacol. Exp. Ther. 46:1994;937-942.